chemieunternehmen.com

Evotec AG and the European Investment Bank („EIB“) announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec’s Innovate strategy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/european-investment-bank-supports-evotecs-innovate-strategy-with-eur-75-m-loan-5498

Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-abivax-enter-into-strategic-collaboration-to-develop-novel-antiviral-agents-5496

Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-aptuit-5492

Evotec AG today reported financial results and corporate updates for the first half of 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-first-half-year-2017-results-and-corporate-update-5490

Evotec AG today announced a strategic collaboration on induced pluripotent stem cell („iPSC“) technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-fraunhofer-ime-sp-sign-strategic-collaboration-on-ipsc-technology-5486

Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-first-half-year-2017-results-on-10-august-2017-5488

Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-acquire-aptuit-expanding-leadership-in-external-innovation-5482

Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics („STORM“) to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-collaboration-with-storm-therapeutics-on-its-rna-epigenetic-platform-5480

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-advance-endometriosis-programme-into-phase-i-clinical-development-and-extend-alliance-5478